Publikation

Pressurized Intraperitoneal Aerosol Chemotherapy-Related Clinical Trials in the Treatment of Peritoneal Metastases

Wissenschaftlicher Artikel/Review - 15.07.2021

Bereiche
Schlagwörter (Tags)
Aerosols/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Humans
Infusions, Parenteral
Peritoneal Neoplasms/drug therapy/*secondary
Pressure
Prospective Studies
ClinicalTrials.gov
Ongoing prospective clinical trials
Peritoneal malignancy therapy
Peritoneal metastases
Pressurized intraperitoneal aerosol chemotherapy
PubMed
DOI
Link
Kontakt

Zitation
Ukegjini K, Putora P, Guidi M, Süveg K, Cihoric N, Widmann B, Steffen T. Pressurized Intraperitoneal Aerosol Chemotherapy-Related Clinical Trials in the Treatment of Peritoneal Metastases. Oncology 2021; 99:601-610.
Projekt
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Oncology 2021; 99
Veröffentlichungsdatum
15.07.2021
ISSN (Druck)
eISSN (Online)
1423-0232
Seiten
601-610
Verlag
Kurzbeschreibung/Zielsetzung

INTRODUCTION
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a treatment option for patients with peritoneal metastases. We evaluated the current status of ongoing prospective clinical trials investigating PIPAC to provide an overview and predict trends in this field.

METHODS
All 367,494 records of clinical trials registered at ClinicalTrials.gov were searched for trials dealing with PIPAC. Active or unpublished trials were further analyzed.

RESULTS
In total, 22 clinical trials were identified and selected for further analyses. Most trials had a single-arm design and were phase I or II. No phase III trials were registered. Academic centers were recorded as primary sponsors in the majority of trials (63.6%). Every year, between 2 and 5 new trials were initiated. In 17 trials (81.8%), PIPAC was used in a palliative setting only, 2 trials performed PIPAC in a neoadjuvant setting, and 2 trials performed PIPAC in an adjuvant setting. Six different drugs (doxorubicin, cisplatin, oxaliplatin, nab-paclitaxel, 5-fluorouracil, and docetaxel) were used in these clinical trials. Most trials investigated the efficacy (n = 15) or safety (n = 7) of PIPAC therapies.

CONCLUSIONS
The results of ongoing clinical trials will bring specific information on indications for PIPAC as well as the impact of PIPAC on quality of life and overall survival.